💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) Tuesday November 7th, 2017By Tokio X'press Cancer, FDA Opdivo
